A genetic strategy involving a glycosyltransferase promoter and a lipid translocating enzyme to eliminate cancer cells.
The most common therapeutic strategy for the treatment of cancer uses antimetabolites, which block uncontrolled division of cancer cells and kill them. However, such antimetabolites also kill normal cells, thus yielding detrimental side effects. This emphasizes the need for an alternative therapy, which would have little or no side effects. Our approach involves designing genetic means to alter surface lipid determinants that induce phagocytosis of cancer cells. The specific target of this strategy has been the enzyme activity termed aminophospholipid translocase (APLT) or flippase that causes translocation of phosphatidylserine (PS) from the outer to the inner leaflet of the plasma membrane in viable cells. Efforts to identify the enigmatic, plasma membrane APLT of mammalian cells have led investigators to some P-type ATPases, which have often proven to be the APLT of internal membranes rather than the plasma membrane. By measuring kinetic parameters for the plasma membrane APLT activity, we have shown that the P-type ATPase Atp8a1 is the plasma membrane APLT of the tumorigenic N18 cells, but not the non-tumorigenic HN2 (hippocampal neuron x N18) cells. Targeted knockdown of this enzyme causes PS externalization in the N18 cells, which would trigger phagocytic removal of these cells. But how would we specifically express the mutants or antisense Atp8a1 in the cancer cells? This has brought us to a glycosyltransferase, GnT-V, which is highly expressed in the transformed cells. By using the GnT-V promoter to drive a luciferase reporter gene we have demonstrated a dramatic increase in luciferase expression selectively in tumor cells. The described strategy could be tested for the removal of cancer cells without the use of antimetabolites that often kill normal cells.
Levano
Kelly
K
CUNY Doctoral Program in Biochemistry, City University of New York at the College of Staten Island, Staten Island, NY 10314, USA.
Sobocki
Tomasz
T
Jayman
Farah
F
Debata
Priya Ranjan
PR
Sobocka
Malgorzata B
MB
Banerjee
Probal
P
D000251:Adenosine Triphosphatases / Q000737:chemistry / Q000235:genetics*; D000595:Amino Acid Sequence; D000818:Animals; D015153:Blotting, Western; D002460:Cell Line; D045744:Cell Line, Tumor; D004591:Electrophoresis, Polyacrylamide Gel; D006801:Humans; D051379:Mice; D016297:Mutagenesis, Site-Directed; D017351:N-Acetylglucosaminyltransferases / Q000235:genetics*; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009447:Neuroblastoma / Q000235:genetics / Q000628:therapy; D049294:Phospholipid Transfer Proteins / Q000737:chemistry / Q000235:genetics* / Q000502:physiology; D011401:Promoter Regions, Genetic / Q000235:genetics*
D049294:Phospholipid Transfer Proteins; D017351:N-Acetylglucosaminyltransferases; C052254:alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase; D000251:Adenosine Triphosphatases; C510547:Atp8a1 protein, mouse